British Journal of Clinical Pharmacology
July 2013
Linda E. Klumpers, Christine Roy, Geraldine Ferron et al.
Cannabinoid receptor type 1 (CB1 ) antagonists have been developed for the treatment of obesity and associated risk factors. Surinabant is a high affinity CB1 antagonist in vitro. The aim of this study was to assess the magnitude of inhibition by surinabant of CNS effects and heart rate induced by Δ(9) -tetrahydrocannabinol (THC) in humans. This was a double-blind, placebo-controlled,...
British Journal of Clinical Pharmacology
February 21, 2013
Marieke Niesters, Christian H. Martini, Albert Dahan
498 citations
The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those that have a neuropathic component. Low dose ketamine produces strong analgesia in neuropathic pain states, presumably by inhibition of the N-methyl-D-aspartate receptor although other mechanisms are possibly involved, including enhancement of descending inhibition and anti-inflammatory effects at central...
British Journal of Clinical Pharmacology
July 2012
Linda E. Klumpers, Tim L Beumer, Johan G C Van Hasselt et al.
• Cannabis based medicines are registered as a treatment for various indications, such as pain and spasms in multiple sclerosis (MS) patients, and anorexia and nausea in patients with HIV or receiving cancer treatment. • the pharmacokinetics of the various administration routes of cannabis and cannabis based medicines are variable and dosing is hard to regulate. • Namisol is a new tablet...
British Journal of Clinical Pharmacology
February 1, 2012
Xiaochen Zhao, Swarajya Lakshmi Vattem Venkata, Ruin Moaddel et al.
136 citations
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • (R,S)‐ketamine is a phencyclidine derivative that was initially developed as an anaesthetic agent and which is currently being studied in the treatment of pain and depression. After administration, the drug is extensively N‐demethylated to (R,S)‐norketamine. The pharmacokinetics of ketamine and norketamine have been extensively studied in volunteers...
British Journal of Clinical Pharmacology
June 2011
Marieke Liem-Moolenaar, Peter de Boer, Maarten Timmers et al.
• The cholinergic system is important for different central nervous system functions, including memory, learning and attention. Scopolamine, a centrally active muscarinic antagonist, has been used to model dementia and to demonstrate the pharmacological effects of cholinergic drugs, but for most effects the concentration-effect relationships are unknown. • We determined the...
British Journal of Clinical Pharmacology
January 2009
Lineke Zuurman, Annelies E Ippel, Eduard Moin et al.
An increasing number of novel therapeutic agents are targeted at cannabinoid receptors. Drug development programmes of new cannabinoid drugs may be facilitated by the identification of useful biomarkers. This systemic literature review aims to assess the usefulness of direct biomarkers for the effects of cannabis and tetrahydrocannabinol (THC) in healthy volunteers. One hundred and sixty-five...
British Journal of Clinical Pharmacology
June 1, 2002
Jordi Riba, P. Anderer, Adelaida Morte et al.
126 citations
Aims Ayahuasca is a traditional South American psychoactive beverage used in Amazonian shamanism, and in the religious ceremonies of Brazilian‐based syncretic religious groups with followers in the US and several European countries. This tea contains measurable amounts of the psychotropic indole N , N ‐dimethyltryptamine (DMT), and β‐carboline alkaloids with MAO‐inhibiting properties. In a...
British Journal of Clinical Pharmacology
February 1, 2000
Rafael de la Torre, Magı́ Farré, Jordi Ortuño et al.
Aims 3,4‐Methylenedioxymethamphetamine (MDMA, commonly called ecstasy) is a synthetic compound increasingly popular as a recreational drug. Little is known about its pharmacology, including its metabolism and pharmacokinetics, in humans in controlled settings. A clinical trial was designed for the evaluation of MDMA pharmacological effects and pharmacokinetics in healthy volunteers. Methods A...
British Journal of Clinical Pharmacology
April 1, 1985
Michael Schächter, David P. Geaney, Dg Grahame‐smith et al.
20 citations
Using a [3H]‐lysergic acid diethylamide [(3H]‐LSD) binding technique, platelet 5‐hydroxytryptamine (5‐HT) receptor number and affinity were compared in schizophrenics treated with depot thioxanthenes and phenothiazines and controls. There was an approximately 30% increase in platelet receptor number (Bmax) in the patient group. There was a decrease in affinity (increase in Kd) of about 30% in...